Table 1. Patient demographics.
| Characteristics (N=53) | Median (Range) |
|---|---|
| Age, yrs | 17 (3–57) |
| Body weight, Kg | 50 (12–89) |
| BSA, m2 | 1.49 (0.56–1.9) |
| Sex | 35 males; 18 females |
| Diagnosis | |
| Aplastic anemia | 40 |
| Fanconi anemia | 13 |
| Regimen | |
| F-araA/Cy | 29 |
| F-araA /Cy/TBI | 20 |
| F-araA /Cy/ATG | 4 |
| Donor source | |
| Matched sibling donor | 45 |
| Alternate donor | 8 |
| Stem cell source | |
| Bone marrow | 2 |
| Peripheral blood | 48 |
| Not evaluable (died prior to Tx) | 3 |
| CD34 cell dose (× 106/kg) | 9.8 (1.3–15.0) |
| HLA Match | |
| <8 | 6 |
| ⩾8 | 47 |
| GvHD prophylaxis | |
| Cyclosporine/Methotrexate | 32 |
| Post Tx Cy | 19 |
| Not Evaluable | 2 |
| SNP frequency in F-araA metabolic pathway genes | |
| NT5E 5′-UTR rs2295890G>C | WT, GG-33 |
| Not available=5 | Var, GC/CC-15 |
| CNT3 Exon 6 rs7853758G>A | WT, GG-32 |
| Not available=7 | Var, GA/AA-14 |
| NT5C2 Intron rs4917996A>C | WT, AA-17 |
| Not available=6 | Var, AC/CC-30 |
| hENT1 Exon 1 rs747199G>C | WT, GG-37 |
| Not available=4 | Var, GC/CC-12 |
Abbreviations: ATG=anti-thymoglobilin; Cy=cyclophosphamide; F-araA=fludarabine; SNP=single-nucleotide polymorphism; Var=variant genotype; WT=wild-type genotype; yrs=years.
Demographics of the patients undergoing HSCT with F-araA/Cy based conditioning regimen with or without TBI/ATG.